Skip to main content

Table 3 Synergy experiments with PI-resistant cell lines

From: Targeting phosphoglycerate dehydrogenase in multiple myeloma

  NCT-503
Cells Proteosome inhibitor IC50 of PI Fold change in IC50 P value
-
NCT
 + 
NCT
INA6-res CTR Carf 3.6 3.2 0.89 0.1404
BTZ 22.7 15.0 0.66  < 0.0001
CR Carf 12.0 7.0 0.58  < 0.0001
BTZ 46.6 25.8 0.55  < 0.0001
BR Carf 3.2 2.9 0.91 0.268
BTZ 59.0 34.3 0.58  < 0.0001
AMO1-res CTR Carf 2.4 2.2 0.92 0.1998
BTZ 24.4 7.2 0.30  < 0.0001
CR Carf 711.0 645.0 0.91 0.1521
BTZ 199.0 113.0 0.57  < 0.0001
BR Carf 25.0 27.0 1.08 0.4697
BTZ 1111.0 581.0 0.52  < 0.0001
  1. INA6-res and AMO1-res cells were treated with 1/3 of their corresponding IC50 of NCT-503 (NCT), in combination with either carfilzomib (Carf) or bortezomib (BTZ). The table summarizes the proteasome inhibitors’ (PI) IC50 values obtained from the graphs shown in Additional file 3: Fig. S3a, b.